The scientific study of the analysis of CBD oil got a major push recently. It's been almost 40 years since the last thorough toxicological safety assessment was run on a CBD oil. However, recently CV sciences had AIBMR Life Sciences Inc. perform a complete array of toxicological studies on Plus CBD oil, the company's consumer-lauded hemp cannabidiol oil. The study attested to the safety of oral consumption of the product.

The study conclusions, which have been shared in a peer-reviewed journal, attest to the fact that the oil was discovered to be non-clastogenic, non-mutagenic and non-genotoxic. A spokesperson for CV Sciences noted that the company was "thrilled" and would encourage all CBD companies to allow such studies to be conducted for their own base materials.

Key Takeaways:

• CV Sciences Inc hired AIBMR Lifesciences Inc. to perform a full toxicological screening of CV's consumer-lauded CBD oil, specifically an extract from the base raw materials comprising it.
• A peer-reviewed journal has published the findings, which indicate that the extract tested is non-mutagenic, non-clastogenic and non-genotoxic.
• A spokesperson for CV Sciences indicated that the company was "thrilled" and also urged other CBD companies to have their base materials tested too.

"The toxicological assessment is the first known published data of its kind since the 1980 Rosenkrantz et al.’s publication with respect to toxicology data on CBD, Cannabichromene and hashish oil."

Read more: http://markets.businessinsider.com/news/stocks/cv-sciences-inc-announces-landmark-publication-on-the-toxicology-and-safety-assessment-of-base-material-of-its-pluscbd-oil-products-1027104828